# US 2020/0270704 A1 · Tumor specific antibodies and t-cell receptors and methods of identifying the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0270704 A1
- Document ID: US20200270704A1
- Status: Published application
- Kind: A1
- Application number: 16/759,371
- Filed: 2018-10-29
- Published: 2020-08-27
- Earliest claimed: 2017-10-27
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, the University of Texas System
- Inventors: Gregory C. IPPOLITO; Jonathan R. MCDANIEL; William N. VOSS; George GEORGIOU
- Web page: https://patentgrep.com/patent/US20200270704A1

## CPC

- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C07K 16/30: from tumour cells
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/54: F(ab')2
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods are provided for identifying tumor-specific antibodies and/or T-cell receptors by paired mRNA sequencing from individual immune cells in sentinel lymph nodes and comparison of these sequences with corresponding mass spectroscopy data from a subject having a cancer. Novel tumor-specific antibodies (e.g., NY-ESO-1-binding antibodies) are also provided.

## Claims

### Claim 1

A method for identifying cancer-specific antibody and/or T-cell receptor (TCR) sequences, comprising:
a) obtaining the mRNA sequences from individual B-cells and/or individual T-cells obtained from a lymph node of a patient having cancer, wherein the B-cells and/or T-cells were obtained from a tumor draining lymph node and wherein the obtained mRNA sequences comprise sequences encoding paired VH and VL and/or paired T-cell receptor polypeptides; and
c) using the mRNA sequences to identify the amino acid sequences encoding the cancer-specific antibody and/or TCR polypeptides.

### Claim 2 (depends on 1)

The method of claim 1, comprising identifying cancer-specific antibody sequences, comprising:
a) obtaining the mRNA sequences from individual B-cells obtained from a lymph node of a patient having cancer, wherein the B-cells were obtained from a tumor draining lymph node and wherein the obtained mRNA sequences comprise sequences encoding paired VH and VL polypeptides from individual B-cells; and
c) using the mRNA sequences to identify the amino acid sequences encoding the cancer-specific antibody polypeptides.

### Claim 3 (depends on 1)

The method of claim 1, comprising identifying cancer-specific T-cell receptor (TCR) sequences, comprising:
a) obtaining the mRNA sequences from individual T-cells obtained from a lymph node of a patient having cancer, wherein the T-cells were obtained from a tumor draining lymph node and wherein the obtained mRNA sequences comprise sequences encoding paired T-cell receptor polypeptides; and
c) using the mRNA sequences to identify the amino acid sequences encoding the TCR polypeptides.

### Claim 4 (depends on 1)

The method of claim 1, comprising identifying cancer-specific antibody and/or T-cell receptor (TCR) sequences, comprising:
a) obtaining the mRNA sequences from individual B-cells and/or individual T-cells obtained from a lymph node of a patient having cancer, wherein the B-cells and/or T-cells were obtained from a tumor draining lymph node and wherein the obtained mRNA sequences comprise sequences encoding paired VH and VL and/or paired T-cell receptor polypeptides;
b) obtaining data showing the actual antibody polypeptides and/or T-cells present in the patient; and
c) using the mRNA sequences and the data to identify the amino acid sequences encoding the cancer-specific antibody and/or TCR polypeptides.

### Claim 5 (depends on 4)

The method of claim 4, comprising:
a) obtaining the mRNA sequences from individual B-cells obtained from a lymph node of a patient having cancer, wherein the B-cells were obtained from a tumor draining lymph node and wherein the obtained mRNA sequences comprise sequences encoding paired VH and VL polypeptides;
b) obtaining mass spectra data of peptides derived from antibody polypeptides from the subject; and
c) using the mRNA sequences and the mass spectra data to identify the amino acid sequences encoding cancer-specific the antibody.

### Claim 6 (depends on 1)

The method of claim 1, wherein the B cells comprise mature B cells.

### Claim 7 (depends on 1)

The method of claim 1, wherein the mature B cells comprise memory B cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein the mature B cells comprise plasma cells.

### Claim 9 (depends on 1)

The method of claim 1, wherein step (b) comprises quantifying the amounts of the peptides derived from antibody polypeptides.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer-specific antibody is an IgG or IgA antibody.

### Claim 11 (depends on 4)

The method of claim 4, comprising:
a) obtaining the mRNA sequences from individual T-cells obtained from a lymph node of a patient having cancer, wherein the T-cells were obtained from a tumor draining lymph node and wherein the obtained mRNA sequences comprise sequences encoding paired T-cell receptor polypeptides; and
c) using the mRNA sequences and the data to identify the amino acid sequences encoding the cancer-specific TCR polypeptides.

### Claim 12 (depends on 1)

The method of claim 1, wherein the T-cells are mature T-cells.

### Claim 13 (depends on 1)

The method of claim 1, wherein the T-cells are CD4+ T-cells.

### Claim 14 (depends on 1)

The method of claim 1, wherein the T-cells are CD8+ T-cells.

### Claim 15 (depends on 1)

The method of claim 1, wherein the T-cells are memory T-cells.

### Claim 16 (depends on 1)

The method of claim 1, wherein the T-cells comprise alpha/beta T-cells.

### Claim 17 (depends on 16)

The method of claim 16, comprising identifying the amino acid sequences encoding the cancer-specific paired alpha and beta TCR polypeptides.

### Claim 18 (depends on 1)

The method of claim 1, wherein the T-cells comprise gamma/delta T-cells.

### Claim 19 (depends on 18)

The method of claim 18, comprising identifying the amino acid sequences encoding the cancer-specific paired gamma and delta TCR polypeptides.

### Claim 20 (depends on 4)

The method of claim 4, wherein the (b) obtaining data showing the actual T-cells present in the patient comprises data showing T-cells in circulation.

### Claim 21 (depends on 4)

The method of claim 4, wherein the (b) obtaining data showing the actual T-cells present in the patient comprises quantifying tumor reactive T-cells in the patient.

### Claim 22 (depends on 20)

The method of claim 20, wherein quantifying tumor reactive T-cells in the patient comprises FACS analysis of the T-cells.

### Claim 23 (depends on 1)

The method of claim 1, producing a mosaic plot of the quantified tumor reactive T-cells in the patient.

### Claim 24 (depends on 1)

The method of claim 1, wherein the tumor draining lymph node is the subsegmental, segmental, lobar, interlobar, hilar, mediastinal, supratrochlear, deltoideopectoral, lateral, pectoral, subscapular, intermediate, subclavicular, superficial inguinal, deep inguinal, popliteal, facial buccinators, facial nasolabial, prostate, mandibular, submental, occipital, mastoid/retroauricular, parotid, deep preauricular, deep infra-auricular, deep intraglandular, deep cervical, deep anterior cervical, pretracheal, paratracheal, prelaryngeal, thyroid, deep lateral cervical, superior deep cervical, inferior deep cervical, retropharyngeal, jugulodigastric, anterior cervical, lateral cervical, supraclavicular, retroaortic, lateral aortic, celiac, gastric, hepatic, splenic, superior mesenteric, mesenteric, ileocolic, mesocolic, inferior mesenteric, or pararectal lymph node.

### Claim 25 (depends on 1)

The method of claim 1, wherein the tumor draining lymph node is a primary tumor draining lymph node.

### Claim 26 (depends on 1)

The method of claim 1, wherein the tumor draining lymph node is a lymph node that drains a tumor metastasis.

### Claim 27 (depends on 1)

The method of claim 1, wherein the tumor is a solid tumor.

### Claim 28 (depends on 1)

The method of claim 1, wherein step a) comprises determining the mRNA sequences from individual B-cells and/or individual T-cells encoding paired VH and VL and/or paired T-cell receptor polypeptides.

### Claim 29 (depends on 1)

The method of claim 1, further comprising producing the identified cancer-specific antibody and/or TCR polypeptide.

### Claim 30 (depends on 1)

The method of claim 1, further comprising identifying the binding target for the identified cancer-specific antibody and/or TCR polypeptide.

### Claim 31 (depends on 30)

The method of claim 30, wherein identifying the binding target for the identified cancer-specific antibody and/or TCR polypeptide, comprises contacting the identified cancer-specific antibody and/or TCR polypeptide with a protein array.

### Claim 32 (depends on 1)

The method of claim 1, further comprising producing a chimeric antigen receptor based on the identified cancer-specific antibody and/or TCR polypeptide.

### Claim 33 (depends on 29)

The method of claim 29, further comprising identifying the binding target for the cancer-specific antibody and/or TCR polypeptide.

### Claim 34 (depends on 33)

The method of claim 33, further comprising measuring the affinity of the cancer-specific antibody and/or TCR polypeptide for its binding target.

### Claim 35 (depends on 1)

The method of claim 1, comprising identifying the amino acid sequences encoding a plurality of cancer-specific antibody and/or TCR polypeptides.

### Claim 36 (depends on 28)

The method of claim 28, further comprising using the mRNA sequences to quantify the number of individual B-cells and/or individual T-cells encoding each unique antibody and/or TCR polypeptide.

### Claim 37 (depends on 36)

The method of claim 36, further comprising producing a mosaic plot of the quantified individual B-cells and/or individual T-cells encoding each unique antibody and/or TCR polypeptide.

### Claim 38 (depends on 36)

The method of claim 36, further comprising selecting one or more unique antibody and/or TCR polypeptides based on the number of individual B-cells and/or T-cells producing the polypeptides and producing the selected cancer-specific antibody and/or TCR polypeptide.

### Claim 39 (depends on 1)

The method of claim 1, wherein the mRNA sequences from individual B-cells and/or individual T-cells are determined by high-throughput DNA sequencing.

### Claim 40 (depends on 39)

The method of claim 39 wherein the high-throughput sequencing comprises sequencing-by-synthesis, sequencing-by-ligation, sequencing-by-hybridization, single molecule DNA sequencing, multiplex polony sequencing, nanopore sequencing, or a combination thereof.

### Claim 41 (depends on 1)

The method of claim 1, wherein step a) involves the use of a thermostable reverse transcriptase.

### Claim 42 (depends on 41)

The method of claim 41, wherein the thermostable reverse transcriptase has proof-reading activity.

### Claim 43 (depends on 5)

The method of claim 5, wherein step b) comprises the use of high-performance liquid chromatography (HPLC).

### Claim 44 (depends on 5)

The method of claim 5, wherein in step b) the mass spectra data is from peptides obtained from the serum of the patient.

### Claim 45 (depends on 5)

The method of claim 5, wherein in step b) the mass spectra data is from peptides obtained from the tumor draining lymph node of the patient.

### Claim 46 (depends on 5)

The method of claim 5, wherein in step b) the mass spectra data is from peptides obtained from the tumor of the patient.

### Claim 47 (depends on 5)

The method of claim 5, wherein step b) further comprises isolating or enriching a selected class of antibodies.

### Claim 48 (depends on 5)

The method of claim 5, wherein step b) further comprises isolating or enriching serum antibodies that bind to a predetermined antigen.

### Claim 49 (depends on 5)

The method of claim 5, wherein step b) further comprises isolating or enriching CDR3-containing fragments of serum antibodies.

### Claim 50 (depends on 5)

The method of claim 5, wherein step b) further comprises preparing CDR3-containing peptide fragments from serum antibodies using a protease that is identified based on the sequence information.

### Claim 51 (depends on 1)

The method of claim 1, further comprising reporting the identified sequence.

### Claim 52 (depends on 5)

The method of claim 5, wherein step a) and/or b) comprises determining the abundancy level of the antibody.

### Claim 53 (depends on 52)

The method of claim 52, further comprising identifying the antibody that exhibit at least a threshold level of abundancy.

### Claim 54 (depends on 53)

The method of claim 53, further comprising producing identified antibody that exhibit at least a threshold level of abundancy.

### Claim 55

An isolated monoclonal antibody, wherein the antibody specifically binds to NY-ESO-1 and comprises:
(I)
(a) a first VH CDR identical to VH CDR1 of BC2-3G1 (GDSVSSNSAA; SEQ ID NO: 1), BC2-3G2 (GDSVSSNSAA; SEQ ID NO: 1), BC2-3G3 (GDSVSSNSAA; SEQ ID NO: 1), BC2-3G4 (GDSVSSNTAA; SEQ ID NO: 2), or BC2-3G0 (GDSVSSNSAA; SEQ ID NO: 1);
(b) a second VH CDR identical to VH CDR2 of BC2-3G1 (TYYRSKWYN; SEQ ID NO: 3), BC2-3G2 (TYYRSKWYS; SEQ ID NO: 4), BC2-3G3 (TYYRSKWYS; SEQ ID NO: 4), BC2-3G4 (TYYRSRWYH; SEQ ID NO: 5), or BC2-3G0 (TYYRSKWYN; SEQ ID NO: 3);
(c) a third VH CDR identical to VH CDR3 of BC2-3G1 (CARDLGIAAAGDFDYW; SEQ ID NO: 6), BC2-3G2 (CARDLGPAAAADFDYW; SEQ ID NO: 7), BC2-3G3 (CARDLGVTAAADFDFW; SEQ ID NO: 8), BC2-3G4 (CARDLGLAAAADFDFW; SEQ ID NO: 9), or BC2-3G0 (CARDLGIAAAGYFDYW; SEQ ID NO: 16);
(d) a first VL CDR identical to VL CDR1 of BC2-3G1 (QGVSSY; SEQ ID NO: 10), BC2-3G2 (QSVSSY; SEQ ID NO: 11), BC2-3G3 (QSVSSY; SEQ ID NO: 11), BC2-3G4 (QSVSSY; SEQ ID NO: 11), or BC2-3G0 (QGVSSY; SEQ ID NO: 10);
(e) a second VL CDR identical to VL CDR2 of BC2-3G1 (DAS; SEQ ID NO: 12), BC2-3G2 (DAS; SEQ ID NO: 12), BC2-3G3 (DAS; SEQ ID NO: 12), BC2-3G4 (DAS; SEQ ID NO: 12), or BC2-3G0 (DAS; SEQ ID NO: 12); and
(f) a third VL CDR identical to VL CDR3 of BC2-3G1 (CHQGSNWPTF; SEQ ID NO: 13), BC2-3G2 (CHQHFNWPTF; SEQ ID NO: 14), BC2-3G3 (CHQHFNWPTF; SEQ ID NO: 14), BC2-3G4 (CHQHRSWPTF; SEQ ID NO: 15) or BC2-3G0 (CQQRSNWLTF; SEQ ID NO: 17); or
(II)
(a) a first VH CDR identical to VH CDR1 of BC2-4G0 (GGSISSY; SEQ ID NO: 18), BC2-4G1 (GGSITNY; SEQ ID NO: 19), or BC2-4G2 (GGSISNY; SEQ ID NO: 20);
(b) a second VH CDR identical to VH CDR2 of BC2-4G0 (IYYSGST; SEQ ID NO: 21), BC2-4G1 (IYYSGNT; SEQ ID NO: 22), or BC2-4G2 (IYYNGNT; SEQ ID NO: 23);
(c) a third VH CDR identical to VH CDR3 of BC2-4G0 (CARHGLGWDLYYFDYW; SEQ ID NO: 24), BC2-4G1 (CARHGLGWDLYYFDYW; SEQ ID NO: 24), or BC2-4G2 (CARHGSGWDLYYFDYW; SEQ ID NO: 25);
(d) a first VL CDR identical to VL CDR1 of BC2-4G0 (SSNIGAGYD; SEQ ID NO: 26), BC2-4G1 (SSNIGAGYD; SEQ ID NO: 26), or BC2-4G2 (SLNIGAGYD; SEQ ID NO: 27); (e) a second VL CDR identical to VL CDR2 of BC2-4G0 (GNS; SEQ ID NO: 28), BC2-4G1 (GNT; SEQ ID NO: 29), or BC2-4G2 (SNN; SEQ ID NO: 30); and
(f) a third VL CDR identical to VL CDR3 of BC2-4G0 (CQSYDSSLSGYVF; SEQ ID NO: 31), BC2-4G1 (CQSYDSSLIGYVF; SEQ ID NO: 32), or BC2-4G2 (CQSYDASLKGYVF; SEQ ID NO: 33); or
(III)
(a) a first VH CDR identical to VH CDR1 of BC2-5G1 (GGTFSSYA; SEQ ID NO: 34), or BC2-5G2 (GGTFSSYA; SEQ ID NO: 34);
(b) a second VH CDR identical to VH CDR2 of BC2-5G1 (IIPILGIA; SEQ ID NO: 35), or BC2-5G2 (IIPILGVT; SEQ ID NO: 36);
(c) a third VH CDR identical to VH CDR3 of BC2-5G1 (CASVTSRYW; SEQ ID NO: 44), or BC2-5G2 (CASVTSGYW; SEQ ID NO: 37);
(d) a first VL CDR identical to VL CDR1 of BC2-5G1 (QSVSSSS; SEQ ID NO: 38), or BC2-5G2 (QSISSSY; SEQ ID NO: 39);
(e) a second VL CDR identical to VL CDR2 of BC2-5G1 (GAS; SEQ ID NO: 40), or BC2-5G2 (SAS; SEQ ID NO: 41); and
(f) a third VL CDR identical to VL CDR3 of BC2-5G1 (CQQHGISPPFMYTF; SEQ ID NO: 42), or BC2-5G2 (CQHYGSSPAFMYTF; SEQ ID NO: 43).

### Claim 56 (depends on 55)

The antibody of claim 55, wherein the antibody is an IgG, IgM, IgA, IgE or an antigen binding fragment thereof.

### Claim 57 (depends on 55, 56)

The antibody of any one of claims 55-56, wherein the antibody is a Fab′, a F(ab′)2, a F(ab′)3, a monovalent scFv, a bivalent scFv, or a single domain antibody.

### Claim 58 (depends on 55, 56)

The antibody of any one of claims 55-56, wherein the antibody is a human, humanized antibody or de-immunized antibody.

### Claim 59 (depends on 55, 56, 57, 58)

The antibody of any one of claims 55-58, wherein the antibody is conjugated to an imaging agent, a chemotherapeutic agent, a toxin or a radionuclide.

### Claim 60 (depends on 55, 56, 57, 58, 59)

A composition comprising an antibody of any one of claims 55-59 in a pharmaceutically acceptable carrier.

### Claim 61 (depends on 55, 56)

An isolated polynucleotide molecule comprising a nucleic acid sequence encoding an antibody VH or VL of any one of claims 55-56.

### Claim 62 (depends on 55, 56)

A host cell comprising one or more polynucleotide molecule(s) encoding an antibody of any one of claims 55-56 or comprising an antibody of anyone of claims 55-56.

### Claim 63 (depends on 62)

The host cell of claim 62, wherein the host cell is a mammalian cell, a yeast cell, a bacterial cell, a ciliate cell or an insect cell.

### Claim 64 (depends on 55, 56)

A method of manufacturing an antibody comprising:
(a) expressing one or more polynucleotide molecule(s) encoding a VL and VH chain of an antibody of any one of claims 55-56 in a cell; and
(b) purifying the antibody from the cell.

### Claim 65 (depends on 55, 56, 57, 58, 59, 60)

A method for treating a subject having a cancer comprising administering an effective amount of an antibody of any one of claims 55-60 to the subject.

### Claim 66 (depends on 65)

The method of claim 65, wherein the cancer is an NY-ESO-1 positive cancer.

### Claim 67 (depends on 65)

The method of claim 65, wherein the cancer is a breast cancer, lung cancer, head & neck cancer, prostate cancer, esophageal cancer, tracheal cancer, skin cancer brain cancer, liver cancer, bladder cancer, stomach cancer, pancreatic cancer, ovarian cancer, uterine cancer, cervical cancer, testicular cancer, colon cancer, rectal cancer, skin cancer, or synovial cancer.

### Claim 68 (depends on 65)

The method of claim 65, wherein the antibody is in a pharmaceutically acceptable composition.

### Claim 69 (depends on 65)

The method of claim 65, wherein the antibody is administered systemically.

### Claim 70 (depends on 65)

The method of claim 65, wherein the antibody is administered intravenously, intradermally, intratumorally, intramuscularly, intraperitoneally, subcutaneously, or locally.

### Claim 71 (depends on 65)

The method of claim 65, further comprising administering at least a second anticancer therapy to the subject.

### Claim 72 (depends on 71)

The method of claim 71, wherein the second anticancer therapy is a surgical therapy, chemotherapy, radiation therapy, cryotherapy, hormonal therapy, immunotherapy or cytokine therapy.

### Claim 73 (depends on 55, 56)

A method for detecting a cancer in a subject comprising testing for the presence of NY-ESO-1 in a sample from the subject, wherein the testing comprises contacting the sample with an antibody of any one of claims 55-56.

### Claim 74 (depends on 73)

The method of claim 73, further defined as an in vitro method.

### Claim 75

A mosaic plot of data showing quantified individual tumor specific B-cells and/or individual tumor specific T-cells encoding each unique antibody and/or TCR polypeptide.

### Claim 76

A computer readable media comprising a mosaic plot of data showing quantified individual tumor specific B-cells and/or individual tumor specific T-cells encoding each unique antibody and/or TCR polypeptide.

### Claim 77

A chimeric antigen receptor (CAR) protein, wherein the CAR protein binds NY-ESO-1 and comprises:
(I)
(a) a first VH CDR identical to VH CDR1 of BC2-3G1 (GDSVSSNSAA; SEQ ID NO: 1), BC2-3G2 (GDSVSSNSAA; SEQ ID NO: 1), BC2-3G3 (GDSVSSNSAA; SEQ ID NO: 1), BC2-3G4 (GDSVSSNTAA; SEQ ID NO: 2), or BC2-3G0 (GDSVSSNSAA; SEQ ID NO: 1);
(b) a second VH CDR identical to VH CDR2 of BC2-3G1 (TYYRSKWYN; SEQ ID NO: 3), BC2-3G2 (TYYRSKWYS; SEQ ID NO: 4), BC2-3G3 (TYYRSKWYS; SEQ ID NO: 4), BC2-3G4 (TYYRSRWYH; SEQ ID NO: 5), or BC2-3G0 (TYYRSKWYN; SEQ ID NO: 3);
(c) a third VH CDR identical to VH CDR3 of BC2-3G1 (CARDLGIAAAGDFDYW; SEQ ID NO: 6), BC2-3G2 (CARDLGPAAAADFDYW; SEQ ID NO: 7), BC2-3G3 (CARDLGVTAAADFDFW; SEQ ID NO: 8), BC2-3G4 (CARDLGLAAAADFDFW; SEQ ID NO: 9), or BC2-3G0 (CARDLGIAAAGYFDYW; SEQ ID NO: 16);
(d) a first VL CDR identical to VL CDR1 of BC2-3G1 (QGVSSY; SEQ ID NO: 10), BC2-3G2 (QSVSSY; SEQ ID NO: 11), BC2-3G3 (QSVSSY; SEQ ID NO: 11), BC2-3G4 (QSVSSY; SEQ ID NO: 11), or BC2-3G0 (QGVSSY; SEQ ID NO: 10);
(e) a second VL CDR identical to VL CDR2 of BC2-3G1 (DAS; SEQ ID NO: 12), BC2-3G2 (DAS; SEQ ID NO: 12), BC2-3G3 (DAS; SEQ ID NO: 12), BC2-3G4 (DAS; SEQ ID NO: 12), or BC2-3G0 (DAS; SEQ ID NO: 12); and
(f) a third VL CDR identical to VL CDR3 of BC2-3G1 (CHQGSNWPTF; SEQ ID NO: 13), BC2-3G2 (CHQHFNWPTF; SEQ ID NO: 14), BC2-3G3 (CHQHFNWPTF; SEQ ID NO: 14), BC2-3G4 (CHQHRSWPTF; SEQ ID NO: 15) or BC2-3G0 (CQQRSNWLTF; SEQ ID NO: 17); or
(II)
(a) a first VH CDR identical to VH CDR1 of BC2-4G0 (GGSISSY; SEQ ID NO: 18), BC2-4G1 (GGSITNY; SEQ ID NO: 19), or BC2-4G2 (GGSISNY; SEQ ID NO: 20);
(b) a second VH CDR identical to VH CDR2 of BC2-4G0 (IYYSGST; SEQ ID NO: 21), BC2-4G1 (IYYSGNT; SEQ ID NO: 22), or BC2-4G2 (IYYNGNT; SEQ ID NO: 23);
(c) a third VH CDR identical to VH CDR3 of BC2-4G0 (CARHGLGWDLYYFDYW; SEQ ID NO: 24), BC2-4G1 (CARHGLGWDLYYFDYW; SEQ ID NO: 24), or BC2-4G2 (CARHGSGWDLYYFDYW; SEQ ID NO: 25);
(d) a first VL CDR identical to VL CDR1 of BC2-4G0 (SSNIGAGYD; SEQ ID NO: 26), BC2-4G1 (SSNIGAGYD; SEQ ID NO: 26), or BC2-4G2 (SLNIGAGYD; SEQ ID NO: 27); (e) a second VL CDR identical to VL CDR2 of BC2-4G0 (GNS; SEQ ID NO: 28), BC2-4G1 (GNT; SEQ ID NO: 29), or BC2-4G2 (SNN; SEQ ID NO: 30); and
(f) a third VL CDR identical to VL CDR3 of BC2-4G0 (CQSYDSSLSGYVF; SEQ ID NO: 31), BC2-4G1 (CQSYDSSLIGYVF; SEQ ID NO: 32), or BC2-4G2 (CQSYDASLKGYVF; SEQ ID NO: 33); or
(III)
(a) a first VH CDR identical to VH CDR1 of BC2-5G1 (GGTFSSYA; SEQ ID NO: 34), or BC2-5G2 (GGTFSSYA; SEQ ID NO: 34);
(b) a second VH CDR identical to VH CDR2 of BC2-5G1 (IIPILGIA; SEQ ID NO: 35), or BC2-5G2 (IIPILGVT; SEQ ID NO: 36);
(c) a third VH CDR identical to VH CDR3 of BC2-5G1 (CASVTSRYW; SEQ ID NO: 44), or BC2-5G2 (CASVTSGYW; SEQ ID NO: 37);
(d) a first VL CDR identical to VL CDR1 of BC2-5G1 (QSVSSSS; SEQ ID NO: 38), or BC2-5G2 (QSISSSY; SEQ ID NO: 39);
(e) a second VL CDR identical to VL CDR2 of BC2-5G1 (GAS; SEQ ID NO: 40), or BC2-5G2 (SAS; SEQ ID NO: 41); and
(f) a third VL CDR identical to VL CDR3 of BC2-5G1 (CQQHGISPPFMYTF; SEQ ID NO: 42), or BC2-5G2 (CQHYGSSPAFMYTF; SEQ ID NO: 43).

### Claim 78 (depends on 55, 56, 57, 58)

A chimeric antigen receptor (CAR) protein, wherein the CAR protein binds NY-ESO-1 and comprises an antibody sequence or an antigen binding fragment thereof in accordance with any one of claims 55-58.

### Claim 79 (depends on 77, 78)

A polynucleotide molecule encoding a CAR protein according to any one of claims 77-78.

### Claim 80 (depends on 79)

An engineered cell comprising a polynucleotide molecule according to claim 79.

### Claim 81 (depends on 80)

The cell of claim 80, wherein the cell is a T cell, such as a cytotoxic T cell.

### Claim 82 (depends on 80)

The cell of claim 80, wherein the cell is an NK Cell.

### Claim 83 (depends on 80)

The cell of claim 80, further comprising a transposase.

### Claim 84 (depends on 80, 81, 82, 83)

A method of treating cancer in a human subject in need thereof comprising administering to the subject an effective amount of a cell therapy comprising one or more cells in accordance with any one of claims 80-83.
